选择性5-羟色胺再摄取抑制剂暴露不影响胚胎非整倍体率
回顾性队列分析显示,在19,464枚胚胎中,3.9%暴露于SSRI,校正混杂因素后SSRI暴露与胚胎非整倍体风险无统计学显著关联(校正OR 0.04;95%CI -0.04-0.09)。在2,132个冻融单胚胎移植周期中,暴露组与未暴露组的着床率、临床妊娠率、流产率及多胎妊娠率均无显著差异。结论认为SSRI暴露不增加胚胎非整倍体率,IVF结局与未暴露患者无差异。
要点
- SSRI暴露与胚胎非整倍体无统计学显著关联(校正OR 0.04;95%CI -0.04-0.09)。
- 冻融单胚胎移植周期中,SSRI暴露组与未暴露组的IVF结局无显著差异。
- 研究结论认为SSRI暴露不增加胚胎非整倍体率。
核心结论
- 体内暴露于SSRI的患者在IVF中胚胎非整倍体率不增加。
- SSRI暴露患者的IVF结局与未暴露患者无差异。
研究设计与样本
- 回顾性队列分析,设置于私立和学术IVF中心。
- 接受IVF并采用滋养外胚层活检进行植入前遗传学检测的患者(n=4,355个周期)。
- 2012年1月至2017年6月期间接受单胚胎移植的患者(n=2,132个周期)。
- 干预措施为全染色体筛查和整倍体单胚胎移植。
主要发现
- 共分析19,464枚胚胎,其中3.9%(n=743)暴露于SSRI,96.1%(n=18,721)未暴露。
- 胚胎整倍体率为52.1%,非整倍体率为42.5%,5.4%的报告结果不确定。
- 各队列间临床和IVF特征无差异。
- 校正混杂因素后,SSRI暴露与非整倍体风险无统计学显著关联(校正OR 0.04;95%CI -0.04-0.09)。
- 在2,132个冻融单胚胎移植周期的亚组分析中,暴露组与未暴露组的着床率(71.3% vs 70.1%;OR 0.60;95%CI 0.60-1.47)、临床妊娠率(58.2% vs 59.7%;OR 0.70;95%CI 0.70-1.61)、流产率(18.5% vs 11.49%;OR 1.54;95%CI 0.94-2.54)及多胎妊娠率(0.6% vs 0;OR 0.7;95%CI 0.02-7.32)均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether maternal exposure to selective serotonin reuptake inhibitors (SSRIs) has any influence on rates of blastocyst aneuploidy and/or in vitro fertilization (IVF) cycle outcomes. DESIGN: Retrospective cohort analysis. SETTING: Private and academic IVF center. PATIENT(S): Patients who underwent IVF with preimplantation genetic treatment with trophectoderm biopsy (n = 4,355 cycles) and patients who underwent a single-embryo transfer (SET) between January-2012 and June-2017 (n = 2,132 cycles). INTERVENTION(S): Comprehensive chromosome screening and euploid SET. MAIN OUTCOME MEASURE(S): Odds of embryo aneuploidy. RESULT(S): Of 19,464 embryos analyzed, 3.9% (n = 743) were exposed to a SSRI, and the remaining 96.1% (n = 18,721) were not. The embryo euploid rate was 52.1%, and the aneuploid rate was 42.5%; 5.4% of the reports were inconclusive. No differences were found in clinical and IVF characteristics among the cohorts. After controlling for cofounders, there was no statistically significant associations between exposure to SSRIs and the odds of aneuploidy (adjusted odds ratio [OR] 0.04; 95% confidence interval [CI], -0.04-0.09). In a subanalysis including 2,132 thawed SET cycles, no differences were observed in implantation rate (71.3% vs. 70.1%; OR 0.60; 95% CI, 0.60-1.47), clinical pregnancy rate (58.2% vs. 59.7%; OR 0.70; 95% CI, 0.70-1.61), loss rate (18.5% vs. 11.49%; OR 1.54; 95% CI, 0.94-2.54), or multiple pregnancy rate (0.6% vs. 0; OR 0.7; 95% CI, 0.02-7.32) between cohorts. CONCLUSION(S): Patients exposed to SSRIs in vivo are not susceptible to an increased rate of embryo aneuploidy in IVF. The IVF outcomes of patients exposed to SSRIs do not differ from those of unexposed patients.
引用
- Hernandez-Nieto C, Lee J, Nazem T, et al. Embryo aneuploidy is not impacted by selective serotonin reuptake inhibitor exposure. Fertil Steril. 2017. PMID: 29202974. doi:10.1016/j.fertnstert.2017.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。